Oncology Venture, Innovation & Partnering Summit

What is the secret code for value creation in oncology innovation? Is it achieved by leveraging AI for care delivery or AI for drug discovery? Is it mechanism, stage, indication, or team? Drug or platform? Data or promise? Heavily capitalized or lean and mean? Do you go where the strategics are hunting or build it so they follow? Join 4 panelists who, through a capital market lens, help crack the code: how to create value in oncology innovation.

What are the high-level priorities of big pharma for oncology deal making? Join our panelists to discuss recent macro trends for deal structure and terms and forward-looking areas of pharma strategic interest in oncology.

Join us for an insightful panel discussion on cancer diagnostics, screening, and early detection. Our panelists will explore the latest advancements in technology and methodologies, discuss the impact of early intervention on patient outcomes, and address current challenges in the field. Gain valuable knowledge on how cutting-edge innovations are shaping the future of cancer care and improving survival rates.

The Oncology Venture, Innovation & Partnering Summit panel will focus on emerging oncology therapeutics and modalities. Oncology therapeutic development remains a pressing area of unmet need for patients and is perennially a high interest area for investors and strategics. We will tour the most compelling areas of the oncology therapeutic landscape, including radiopharmaceuticals, antibody drug conjugates, therapies targeting genetic drivers and synthetic lethality, as well as promising areas within immuno-oncology.

AI’s presence in oncology is undeniable, but its true impact depends on thoughtful integration. This panel examines how AI can be effectively woven into the cancer care continuum, from early drug discovery to clinical practice, ensuring that innovation translates into tangible benefits for clinicians, researchers, and patients.

Biopharma companies need more trial participants. Regulators and payers want more representative trial populations. Patient advocacy groups desire earlier and wider access to clinical trials. Are there ways to improve access to clinical trials in community settings? How can barriers to trial participation be reduced? Where speed is critical, how can access to innovative treatments be ensured on a timely basis? Are win-win approaches possible?

We are at a critical crossroad in cancer innovation: with more cancer drugs approved in the past 5 years than in the prior 15 years, and more than 50% of clinical trials focusing on cancer patients, how do we make sure we do not only improve outcomes for individual patients but also address rather than exacerbate disparities in cancer care? What needs to change to unlock the rapid dissemination of innovation and the development of the right therapies and technologies to address existing and emerging cancer disparities? This panel will discuss how technology, AI, novel care delivery models, evolving regulatory approaches, and new reimbursement and business models can drive guideline-concordant care, address cancer disparities and inequities, and unlock diversity in clinical trials. We will also explore the convergence of technology with value-based care and how improving the patient experience—in partnership with patients—can support health equity and improve patient outcomes for everyone.